The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
Open accessAbstract
BACKGROUND: Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such plasma contains potentially therapeutic antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be passively transferred to the plasma recipient. Whether convalescent plasma with high antibody levels rather than low antibody levels is associated with a lower risk of death is unknown. METHODS: In a retrospective study based on a U.S. national registry, we determined the anti-SARS-CoV-2 IgG antibody levels in convalescent plasma used to treat hospitalized adults with Covid-19. The primary outcome was death within 30 days after plasma transfusion. Patients who were enrolled through July 4, 2020, and for whom data on anti-SARS-CoV-2 antibody levels in plasma transfusions and on 30-day mortality were available were included in the analysis. RESULTS: Of the 3082 patients included in this analysis, death within 30 days after plasma transfusion occurred in 115 of 515 patients (22.3%) in the high-titer group, 549 of 2006 patients (27.4%) in the medium-titer group, and 166 of 561 patients (29.6%) in the low-titer group. The association of anti-SARS-CoV-2 antibody levels with the risk of death from Covid-19 was moderated by mechanical ventilation status. A lower risk of death within 30 days in the high-titer group than in the low-titer group was observed among patients who had not received mechanical ventilation before transfusion (relative risk, 0.66; 95% confidence interval [CI], 0.48 to 0.91), and no effect on the risk of death was observed among patients who had received mechanical ventilation (relative risk, 1.02; 95% CI, 0.78 to 1.32). CONCLUSIONS: Among patients hospitalized with Covid-19 who were not receiving mechanical ventilation, transfusion of plasma with higher anti-SARS-CoV-2 IgG antibody levels was associated with a lower risk of death than transfusion of plasma with lower antibody levels. (Funded by the Department of Health and Human Services and others; ClinicalTrials.gov number, NCT04338360.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
The REDCap consortium: building an international community of software platform partners
Harris, P. A., Taylor, R., Minor, B. L., Elliott, V., Fernandez, M., O'Neal, L., McLeod, L., Delacqua, G., Delacqua, F., Kirby, J., et al. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2019.103208 · Cited by 24,013
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,960
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022926 · Cited by 1,265
Spinner, C. D., Gottlieb, R. L., Criner, G. J., Arribas López, J. R., Cattelan, A. M., Soriano Viladomiu, A., Ogbuagu, O., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,211
Li, L., Zhang, W., Hu, Y., Tong, X., Zheng, S., Yang, J., Kong, Y., Ren, L., Wei, Q., Mei, H., et al. (2020) · JAMA · doi:10.1001/jama.2020.10044 · Cited by 1,206
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
Self-citationAgarwal, A., Mukherjee, A., Kumar, G., Chatterjee, P., Bhatnagar, T., & Malhotra, P. (2020) · BMJ · doi:10.1136/bmj.m3939 · Cited by 718
Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?
Luke, T. C., Kilbane, E. M., Jackson, J. L., & Hoffman, S. L. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00139 · Cited by 636
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Liu, S. T. H., Lin, H.-M., Baine, I., Wajnberg, A., Gumprecht, J. P., Rahman, F., Rodriguez, D., Tandon, P., Bassily-Marcus, A., Bander, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1088-9 · Cited by 493
Self-citationEarly safety indicators of COVID-19 convalescent plasma in 5000 patients
Joyner, M. J., Wright, R. S., Fairweather, D., Senefeld, J. W., Bruno, K. A., Klassen, S. A., Carter, R. E., Klompas, A. M., Wiggins, C. C., Shepherd, J. R. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140200 · Cited by 471
Self-citationJoyner, M. J., Bruno, K. A., Klassen, S. A., Kunze, K. L., Johnson, P. W., Lesser, E. R., Wiggins, C. C., Senefeld, J. W., Klompas, A. M., Hodge, D. O., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.06.028 · Cited by 398
Self-citationPiechotta, V., Chai, K. L., Valk, S. J., Doree, C., Monsef, I., Wood, E. M., Lamikanra, A., Kimber, C., McQuilten, Z., So-Osman, C., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600.pub2 · Cited by 367
Zeng, Q.-L., Yu, Z.-J., Gou, J.-J., Li, G.-M., Ma, S.-H., Zhang, G.-F., Xu, J.-H., Lin, W.-B., Cui, G.-L., Zhang, M.-M., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa228 · Cited by 330
Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases
Casadevall, A., & Scharff, M. D. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.1.150 · Cited by 318
Self-citationTreatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma
Salazar, E., Perez, K. K., Ashraf, M., Chen, J., Castillo, B., Christensen, P. A., Eubank, T., Bernard, D. W., Eagar, T. N., Long, S. W., et al. (2020) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.05.014 · Cited by 289
Serum therapy revisited: animal models of infection and development of passive antibody therapy
Casadevall, A., & Scharff, M. D. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.8.1695 · Cited by 251
Self-citationSalazar, E., Christensen, P. A., Graviss, E. A., Nguyen, D. T., Castillo, B., Chen, J., Lopez, B. V., Eagar, T. N., Yi, X., Zhao, P., et al. (2020) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.08.001 · Cited by 230
Salazar, E., Kuchipudi, S. V., Christensen, P. A., Eagar, T., Yi, X., Zhao, P., Jin, Z., Long, S. W., Olsen, R. J., Chen, J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141206 · Cited by 213
Abolghasemi, H., Eshghi, P., Cheraghali, A. M., Imani Fooladi, A. A., Bolouki Moghaddam, F., Imanizadeh, S., Moeini Maleki, M., Ranjkesh, M., Rezapour, M., Bahramifar, A., et al. (2020) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2020.102875 · Cited by 188
Luchsinger, L. L., Ransegnola, B. P., Jin, D. K., Muecksch, F., Weisblum, Y., Bao, W., George, P. J., Rodriguez, M., Tricoche, N., Schmidt, F., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02005-20 · Cited by 187
Chai, K. L., Valk, S. J., Piechotta, V., Kimber, C., Monsef, I., Doree, C. J., Wood, E. M., Lamikanra, A., Roberts, D. J., McQuilten, Z., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600.pub3 · Cited by 162
Hark back: Passive immunotherapy for influenza and other serious infections
Luke, T. C., Casadevall, A., Watowich, S. J., Hoffman, S. L., Beigel, J. H., & Burgess, T. H. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d44c1e · Cited by 150
Self-citationPerotti, C., Baldanti, F., Bruno, R., Fante, C. D., Seminari, E. M., Casari, S., Percivalle, E., Glingani, C., Musella, V., Belliato, M., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.261784 · Cited by 136
Use of convalescent plasma in hospitalized patients with COVID-19: case series
Hegerova, L. T., Gooley, T. A., Sweerus, K. A., Maree, C. L., Bailey, N., Bailey, M., Dunleavy, V., Patel, K., Alcorn, K. W., Haley, R., et al. (2020) · Blood · doi:10.1182/blood.2020006964 · Cited by 133
Rasheed, A. M., Fatak, D. F., Hashim, H. A., et al. (2020) · PubMed · Cited by 121
Rogers, R., Shehadeh, F., Mylona, E. K., Rich, J. D., Neill, M. A., Touzard-Romo, F., Geffert, S. F., Larkin, J. M., Bailey, J. A., Lu, S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1548 · Cited by 64
Modernising epidemic science: enabling patient-centred research during epidemics
Rojek, A. M., & Horby, P. (2016) · BMC Medicine · doi:10.1186/s12916-016-0760-x · Cited by 42
Omrani, A. S., Zaqout, A., Baiou, A., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26537 · Cited by 35
Cited by
Mechanisms of SARS-CoV-2 entry into cells
Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,022
Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00897-7 · Cited by 492
Self-citationPiechotta, V., Chai, K. L., Valk, S. J., Doree, C., Monsef, I., Wood, E. M., Lamikanra, A., Kimber, C., McQuilten, Z., So-Osman, C., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600.pub2 · Cited by 367
Gharbharan, A., Jordans, C. C. E., GeurtsvanKessel, C., den Hollander, J. G., Karim, F., Mollema, F. P. N., Stalenhoef – Schukken, J. E., Dofferhoff, A., Ludwig, I., Koster, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23469-2 · Cited by 347
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265
Metadata
- Authors
- Joyner, M. J., Carter, R. E., Senefeld, J. W., Klassen, S. A., Mills, J. R., Johnson, P. W., Theel, E. S., Wiggins, C. C., Bruno, K. A., Klompas, A. M., Lesser, E. R., Kunze, K. L., Sexton, M. A., Diaz Soto, J. C., Baker, S. E., Shepherd, J. R. A., van Helmond, N., Verdun, N. C., Marks, P., van Buskirk, C. M., Winters, J. L., Stubbs, J. R., Rea, R. F., Hodge, D. O., Herasevich, V., Whelan, E. R., Clayburn, A. J., Larson, K. F., Ripoll, J. G., Andersen, K. J., Buras, M. R., Vogt, M. N. P., Dennis, J. J., Regimbal, R. J., Bauer, P. R., Blair, J. E., Paneth, N. S., Fairweather, D., Wright, R. S., & Casadevall, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-03-18
- Volume
- 384
- Issue
- 11
- Pages
- 1015-1027
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3118278606
- Cited by
- 509
- References
- 32
- FWCI
- 36.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.